Pavlos Msaouel is a Primary Care physician affiliated with The University of Texas MD Anderson Cancer Center. OpenAlex indexes 444 publications with 6,764 citations (h-index 44); ClinicalTrials.gov lists 6 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Internal Medicine profiles in the FindMyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingClinical trials
- Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma
Sponsor: M.D. Anderson Cancer Center
- Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma
Sponsor: M.D. Anderson Cancer Center
- Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies
Sponsor: M.D. Anderson Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Mirati TherapeuticsProgram year20251 paymentResearch$899,075openpaymentsdata.cms.gov ↗
- RegeneronProgram year20251 paymentResearch$350,000openpaymentsdata.cms.gov ↗
- Exelixis Inc.Program year202533 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
NIH funding
2 NIH research awards on record, funded 2024–2026 per NIH RePORTER. The latest:
- Mechanisms of Hyperprogression to Immunotherapy in SMARCB1-Deficient Renal Malignancies
University of Tx Md Anderson Can Ctr
FY2026$672,300R37CA288448 - Elucidating T Cell Ferroptosis in Renal Medullary Carcinoma: 3D Genome Architecture Rewiring and Therapeutic Alleviation
University of Tx Md Anderson Can Ctr
FY2026$671,046R01CA285454 - Mechanisms of Hyperprogression to Immunotherapy in SMARCB1-Deficient Renal Malignancies
University of Tx Md Anderson Can Ctr
FY2025$672,300R37CA288448
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
Fei Wang, MD
Cornell University
Michael Hassman, DO
Barbara Rizzardi, MD
Kimball Johnson, MD
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”